Claims
- 1. A substantially pure A-lineage conotoxin peptide selected from the group consisting of:
- Gly-Cys-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Pro-Asn-Tyr-Gly-Cys-Gly-Thr-Ser-Cys-Ser-Xaa.sub.1 (SEQ ID NO: 10), wherein Xaa.sub.1 is des-Xaa.sub.1 or Arg-Thr-Leu;
- (Gly-Cys-Cys-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys (SEQ ID NO: 12);
- Arg-Asp- Xaa.sub.1 -Cys-Cys-Tyr-His-Pro-Thr-Cys-Asn-Met-Ser-Asn-Pro-Gln-Ile-Cys (SEQ ID NO: 13), wherein Xaa.sub.1 is Pro or hydroxy-Pro;
- Gly-Cys-Cys-Ser-His-Xaa.sub.1 -Ala-Cys-Ser-Val-Asn-Asn-Xaa.sub.2 -Xaa.sub.3 -Ile-Cys (SEQ ID NO: 14), wherein Xaa.sub.1 or Xaa.sub.2 is Pro or hydroxy-Pro, and Xaa.sub.3 is Asp or .beta.-carboxyaspartate;
- Glu-Cys-Cys-Thr-His-Xaa.sub.1 -Ala-Cys-His-Val-Ser-His-Xaa.sub.2 -Glu-Leu-Cys (SEQ ID NO: 15), wherein Xaa.sub.1 or Xaa.sub.2 is Pro or hydroxy-Pro;
- Asp-Tyr-Cys-Cys-His-Arg-Gly-Pro-Cys-Met-Val-Trp-Cys (SEQ ID NO: 16);
- Gln-Asn-Cys-Cys-Ser-Ile-Pro-Ser-Cys-Trp-Glu-Lys-Tyr-Lys-Cys-Xaa.sub.1 (SEQ ID NO: 17), wherein Xaa.sub.1 is Ser or Asn;
- Gly-Cys-Cys-Ala-Ile-Arg-Glu-Cys-Arg-Leu-Gln-Asn-Ala-Ala-Tyr-Cys-Gly-Gly-Ile-Tyr (SEQ ID NO: 18);
- Gly-Cys-Cys-Ser-Asn-Xaa.sub.1 -Val-Cys-His-Leu-Glu-His-Ser-Asn-Leu-Cys (SEQ ID NO: 19), wherein Xaa.sub.1 is Pro or hydroxy-Pro;
- Gly-Gly-Cys-Cys-Ser-Phe-Xaa.sub.1 -Ala-Cys-Arg-Lys-Tyr-Arg-Xaa.sub.2 -Xaa.sub.3 -Met-Cys-Gly (SEQ ID NO:20), wherein Xaa.sub.1 or Xaa.sub.2 is Pro or hydroxy-Pro, and Xaa.sub.3 is Glu or .gamma.-carboxyglutmate:
- Ala-Cys-Cys-Ser-Tyr-Xaa.sub.1 -Pro-Cys-Asn-Val-Asn-Tyr-Xaa.sub.2 -Xaa.sub.3 -Ile-Cys-Gly-Gly-Arg (SEQ ID NO:21), wherein Xaa.sub.1 or Xaa.sub.2 is Pro or hydroxy-Pro, and Xaa.sub.3 is Glu or .gamma.-carboxyglutamate;
- Asn-Gly-Cys-Cys-Arg-Asn-Pro-Ala-Cys-Glu-Ser-His-Arg-Cys-Gly (SEQ ID NO:22);
- Asn-Val-Val-Val-Thr-Ser-Phe-Glu-Pro-Thr-Thr-Leu-Ala-Pro-Val-Pro-Ser-Asp- Cys-Cys-Gln-Val-Ser-Ser-Cys-Trp-Asn-Leu-Tyr-Gly-Leu-Glu-Cys-Thr-Gly-Ile-Thr-Arg- Arg-Arg-Thr-Leu (SEQ ID NO:23);
- Asn-Val-Ala-Ile-Thr-Ser-Phe-Glu-Pro-Thr-Thr-Leu-Ala-Pro-Val-Pro-Ser-Asp- Cys-Cys-Gln-Val-Ser-Ser-Cys-Trp-Asn-Leu-Tyr-Gly-Pro-Glu-Cys-Thr-Gly-Ile-Thr-Arg-Arg-Arg-Thr-Leu (SEQ ID NO:24);
- Arg-Asp-Xaa.sub.1 -Cys-Cys-Tyr-His-Pro-Thr-Cys-Asn-Met-Ser-Asn-Pro-Gln-Ile-Cys (SEQ ID NO:31), wherein Xaa.sub.1 is Pro or hydroxy-Pro and;
- Arg-Asp-Xaa.sub.1 -Cys-Cys-Ser-Asn-Pro-Ala-Cys-Asn-Val-Asn-Asn-Pro-Gln-Ile-Cys (SEQ ID NO: 32), wherein Xaa.sub.1 is Pro or hydroxy-Pro.
- 2. An A-lineage conotoxin peptide of claim 1 wherein one or more of the Pro residues is hydroxy-Pro.
- 3. An A-lineage peptide of claim 1 wherein a Glu residue is .gamma.-carboxyglutamate.
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of application Ser. No. 08/084,848, filed Jun. 29, 1993, now U.S. Pat. No. 5,432,155 which is incorporated herein by reference.
Government Interests
This invention was made with Government support under Grant No. GM-22737 awarded by the National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5270170 |
Schatz et al. |
Dec 1993 |
|
Non-Patent Literature Citations (3)
Entry |
Olivera et al. 1990. Science 249:257-263. |
Olivera et al. 1991. J. Biol. Chem 266(33):22067-22070. |
Ramilo et al. 1992. Biochemists, 31:9919-9926. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
84848 |
Jun 1993 |
|